Slingshot members are tracking this event:
REVLIMID (Lenalidomide) Approved by the European Commission for the Treatment of Relapsed/Refractory Patients with Mantle Cell Lymphoma
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
In the study, the most frequently observed adverse reactions which occurred more frequently in the REVLIMID arm compared with the IC arm were neutropenia (50.9%), anaemia (28.7%), diarrhoea (22.8%), fatigue (21.0%), constipation (17.4%), pyrexia (16.8%), and rash (16.2%).The EC decision for the use of REVLIMID in adult patients with relapsed/refractory MCL follows the positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) earlier this year. The EC decision marks the 6th new product or indication granted to Celgene in the last 18 months in the European Union. In 2015, Celgene announced the EC approval of medicines for newly diagnosed multiple myeloma, another form of blood cancer; psoriasis and psoriatic arthritis; a specific subset of acute myeloid leukaemia (AML) patients; and non-small-cell lung cancer (NSCLC).
Slingshot Insights Explained
Jul 15, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Mantle Cell Lymphoma, Lenalidomide, Revlimid